QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:CDMO

Avid Bioservices (CDMO) Stock Forecast, Price & News

$11.85
-0.67 (-5.35%)
(As of 05/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.80
$12.40
50-Day Range
$11.69
$22.15
52-Week Range
$11.30
$34.51
Volume
789,581 shs
Average Volume
626,898 shs
Market Capitalization
$731.67 million
P/E Ratio
74.07
Dividend Yield
N/A
Beta
2.3
30 days | 90 days | 365 days | Advanced Chart
Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

Avid Bioservices logo

About Avid Bioservices

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDMO
Employees
252
Year Founded
N/A

Sales & Book Value

Annual Sales
$95.87 million
Cash Flow
$0.24 per share
Book Value
$1.28 per share

Profitability

Net Income
$11.21 million
Pretax Margin
12.13%

Debt

Price-To-Earnings

Miscellaneous

Free Float
60,824,000
Market Cap
$731.67 million
Optionable
Optionable

Company Calendar

Last Earnings
3/08/2022
Today
5/16/2022
Next Earnings (Estimated)
7/05/2022
Fiscal Year End
4/30/2023

MarketRank

Overall MarketRank

2.48 out of 5 stars

Medical Sector

150th out of 1,423 stocks

Pharmaceutical Preparations Industry

56th out of 678 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -













Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

Is Avid Bioservices a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avid Bioservices stock.
View analyst ratings for Avid Bioservices
or view top-rated stocks.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Tuesday, July 5th 2022.
View our earnings forecast for Avid Bioservices
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) announced its quarterly earnings results on Tuesday, March, 8th. The biopharmaceutical company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.01. The biopharmaceutical company earned $31.51 million during the quarter, compared to analysts' expectations of $28 million. Avid Bioservices had a net margin of 12.13% and a trailing twelve-month return on equity of 27.58%. During the same period in the previous year, the business posted $0.01 EPS.
View Avid Bioservices' earnings history
.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Avid Bioservices's stock reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its FY 2022 earnings guidance on Tuesday, April, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $115 million-$117 million, compared to the consensus revenue estimate of $116.79 million.

What price target have analysts set for CDMO?

4 equities research analysts have issued twelve-month target prices for Avid Bioservices' stock. Their forecasts range from $28.00 to $32.00. On average, they anticipate Avid Bioservices' stock price to reach $29.50 in the next year. This suggests a possible upside of 148.9% from the stock's current price.
View analysts' price targets for Avid Bioservices
or view top-rated stocks among Wall Street analysts.

Who are Avid Bioservices' key executives?
Avid Bioservices' management team includes the following people:
  • Mr. Nicholas Stewart Green B.Sc., MBA, Pres, CEO & Director (Age 57, Pay $1.55M) (LinkedIn Profile)
  • Mr. Daniel R. Hart, Chief Financial Officer (Age 49, Pay $899.28k) (LinkedIn Profile)
  • Mr. Mark R. Ziebell J.D., VP, Gen. Counsel & Corp. Sec. (Age 58, Pay $707.75k) (LinkedIn Profile)
  • Mr. Richard Richieri, Chief Operations Officer (Age 57)
  • Ms. Lorna Larson, Sr. Director of HR
  • Mr. Matthew Kwietniak, Chief Commercial Officer
  • Dr. Shelley P. M. Fussey, VP of Intellectual Property (Age 56)
  • Ms. Tracy L. Kinjerski, VP of Bus. Operations
  • Dr. Harold F. Dvorak, Medical & Scientific Advisor
  • Prof. Alan J. Schroit, Medical & Scientific Advisor
What is Roger Lias' approval rating as Avid Bioservices' CEO?

2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among Avid Bioservices' employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.68%), State Street Corp (7.13%), Vanguard Group Inc. (6.66%), Invesco Ltd. (2.76%), Geneva Capital Management LLC (2.25%) and Jennison Associates LLC (2.04%). Company insiders that own Avid Bioservices stock include Daniel R Hart, Mark R Bamforth, Mark R Ziebell, Nicholas Stewart Green and Richard B Hancock.
View institutional ownership trends for Avid Bioservices
.

Which major investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Federated Hermes Inc., Northern Trust Corp, Citigroup Inc., Palisade Capital Management LLC NJ, Dimensional Fund Advisors LP, Peregrine Capital Management LLC, and Rhumbline Advisers. Company insiders that have sold Avid Bioservices company stock in the last year include Daniel R Hart, Mark R Ziebell, Nicholas Stewart Green, and Richard B Hancock.
View insider buying and selling activity for Avid Bioservices
or view top insider-selling stocks.

Which major investors are buying Avid Bioservices stock?

CDMO stock was purchased by a variety of institutional investors in the last quarter, including Geneva Capital Management LLC, State Street Corp, Jennison Associates LLC, Wellington Management Group LLP, Royce & Associates LP, Rothschild & Co. Asset Management US Inc., Parkman Healthcare Partners LLC, and Vanguard Group Inc..
View insider buying and selling activity for Avid Bioservices
or or view top insider-buying stocks.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $11.85.

How much money does Avid Bioservices make?

Avid Bioservices has a market capitalization of $731.67 million and generates $95.87 million in revenue each year. The biopharmaceutical company earns $11.21 million in net income (profit) each year or $0.159990 on an earnings per share basis.

How many employees does Avid Bioservices have?

Avid Bioservices employs 252 workers across the globe.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is www.avidbio.com.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at [email protected], or via fax at 714-838-5817.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.